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a  b  s  t  r  a  c  t
There  is conﬂicting  evidence  on  the  causal  relationship  of patent  foramen  ovale  (PFO)  in migraine.  This
review  will  examine  the  pathophysiological  relevance  of PFO  in  migraine,  the epidemiological  evidence
of PFO  causing  migraine,  and  the  existing  evidence  on  the  effectiveness  of  closure  of  PFO on  the  sympto-
matology  of  migraine.  From  the  current  available  evidence,  the role  of PFO  in migraine  is debatable,  andccepted 4 December 2012
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interventions  such  as  closure  of  PFO  cannot  yet  be  considered  routine  treatment  of migraine.
© 2013  Japanese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.igraine
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ntroduction
In utero, the foramen ovale serves as a conduit for right-to-left
hunting of oxygenated blood from the placenta into the systemic
irculation. At birth, as the pulmonary circulation establishes, the
ncreasing left atrial pressure causes functional closure of the fora-
en  ovale. The anatomical closure of the atrial septum primum
nd septum secundum usually occurs by 1 year of age. When
here is incomplete closure of the ﬂap-like opening between the
eptum primum and septum secundum, a patent foramen ovale
PFO) ensues. Migraine is a common, recurrent and often disabling
eadache disorder, typically characterized by unilateral headache
Classiﬁcation of Headache Disorders (ICHD-2) organized by the
International Headache Society [1].
There is debate within the cardiology and neurology communi-
ties as to whether there is a causal relationship between PFO and
migraine. This article will review the evidence for and against this
relationship.
Possible pathophysiological mechanism(s) for the
PFO–migraine relationship
PFO accounts for 95% of all right-to-left shunts [2].  One  possi-
ble mechanism which implicates a role for the right-to-left shuntwith or without aura) of pulsating quality, which is associated
ith nausea, photophobia, and phonophobia. The diagnosis of
igraine is made based on criteria laid down in the International
∗ Corresponding author at: The Walton Centre NHS Foundation Trust, Lower Lane,
iverpool L9 7LJ, UK. Tel.: +44 151 5298151; fax: +44 151 5295512.
E-mail address: s sathasivam@hotmail.com (S. Sathasivam).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.12.005in the development of migraine is that subclinical emboli and
metabolites from the venous system bypass the pulmonary cir-
culation via the PFO, thus entering the systemic circulation and
resulting in irritation of the trigeminal nerve and brain vascula-
ture, which in turn triggers migraine (Table 1). One such metabolite
is serotonin which is normally metabolized by the pulmonary
monoamine oxidase enzyme. Serotonin is released from aggregat-
ing platelets. Platelet activation and aggregation has been shown
to be increased in patients with migraine [3].  In the presence of a
vier Ltd. All rights reserved.
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FO, serotonin is shunted away from the lungs and is postulated to
rigger migraine [4]. Furthermore, a small double-blind crossover
tudy has shown that aspirin, an anti-platelet drug which might be
xpected to reduce the formation of platelet–ﬁbrin complexes and
hus improve migraine, has a statistically signiﬁcant prophylactic
ffect in migraine [5].
Another postulated mechanism related to the PFO–migraine
xis is that transient hypoxemia due to shunting of blood through
he PFO causes microinfarcts in the brain, leading to irritation and a
endency for migraine (Table 1) [4,6]. Resting and stress hypoxemia
elated to left-to-right shunting (paradoxical embolism) across a
FO has been demonstrated in the absence of pulmonary embolism
7]. Various etiologies that predispose to hypoxia or thrombosis in
he presence of a PFO may  predispose to migraine by promoting
ubclinical ischemia and paradoxical embolism [8–10].
The salient shortcomings of the possible pathophysiological
xplanations for the PFO–migraine relationship have been expertly
eviewed by Gupta (Table 2) [11]. It is unlikely that the passage of
ubclinical emboli and metabolites would stream into and lodge
t exactly the same areas of the brain to cause the typical lat-
ralizing and often cyclical (e.g. menstrual migraine) headaches
ver decades in patients, as embolic events are characteristically
npredictable phenomena [12]. It is also well known that most
atients with PFO are asymptomatic [13], while not all migraine
atients have a PFO [11]. PFO is present at birth and will persist
or life if it does not close spontaneously. However, migraine typi-
ally does not start at birth, but rather in adolescence or early adult
ife, thus arguing against the relevance of PFO in migraine. Fur-
hermore, although the size of a PFO increases from the ﬁrst to the
enth decade of life [14], migraine attacks generally tend to sub-
ide with advancing age. The prevalence of PFO is similar in men
nd women [15], but migraine has been reported to be up to twice
s common in women compared to men  [16]. The beta-blocker pro-
ranolol promotes platelet activation and aggregation [17], but is
n effective migraine prophylactic drug. This is opposite of what
ould have been expected if a PFO was a causal factor in migraine.
n addition, migraine is frequent in young patients with ischemic
able 1
ossible pathophysiological mechanisms of patent foramen ovale (PFO) in migraine.
(a) Right-to-left shunting allows subclinical emboli and metabolites from the
venous system to bypass the pulmonary circulation via the PFO, and
entering the systemic circulation and resulting in irritation of the
trigeminal nerve and brain vasculature
(b) Transient hypoxemia due to paradoxical shunting of blood through the PFO
causes microinfarcts in the brain, leading to irritation and a tendency for
migraine – any etiology that predisposes to hypoxia or thrombosis may  be
a  factor
able 2
rguments against the pathophysiological mechanisms of patent foramen ovale
PFO) in migraine.
(a) Embolic events are unpredictable, but migraine headaches are typically
lateralizing and usually cyclical phenomena
(b) Most individuals with PFO do not have migraine
(c)  Not all migraine patients have a PFO
(d) PFO is present from birth if it does not close spontaneously, but migraine
onset is typically in adolescence or early adult life
(e)  The size of a PFO increases with age, but migraine attacks typically subside
with advancing age
(f) Prevalence of PFO is similar in men  and women, but prevalence of migraine
is up to twice as common in women compared to men
(g) Propranolol promotes platelet activation and aggregation, but it is an
effective migraine prophylactic drug
(h) Migraine is frequent in young patients with ischemic stroke, but infrequent
in  older patients with ischemic stroke, although the PFO defect size is
smaller in younger compared to older patients
(i)  Right-to-left shunting does not increase white matter lesion load in
migraine patientsf Cardiology 61 (2013) 256–259 257
stroke, but infrequent in older patients with ischemic stroke [18].
This would be against the hypothesis that PFO is a causal factor
for migraine, as the younger cohort will have relatively smaller
PFO defects. Although white matter lesions are commonly found
on brain magnetic resonance imaging of migraine patients [19,20],
the presence of right-to-left shunting does not increase this lesion
load in patients with migraine, arguing against the importance of
the paradoxical embolism theory leading to microinfarcts in the
brain in patients with migraine [21].
Evidence from epidemiology studies
The frequency of PFO in the population has been reported at
15–35% in autopsy studies [14,22,23],  and appears to decrease with
age [14]. In vivo studies with transesophageal echocardiography
(TOE) have reported a prevalence of PFO in the population of 24%,
which is similar to that of autopsy studies [24]. The prevalence of
PFO has been described to be similar across different race–ethnic
groups [25]. On the other hand, the lifetime prevalence of migraine
ranges from 11% in males to 20% in females, with a mean of 16%
[26]. Most studies only report prevalence strictly complying with
all the criteria of either migraine without (ICHD-2 1.1) or with aura
(ICHD-2 1.2). However, if probable migraine (ICHD-2 1.6), where
cases fulﬁll all but one of the criteria, is included, the prevalence of
migraine almost doubles [27].
It is obvious that PFO and migraine are common conditions in
the population. The next question is whether PFOs are found more
commonly in people who  suffer from migraine which would lend
support to the causal relationship between PFO and migraine. Two
Italian groups were the ﬁrst to report in case–control studies using
transcranial Doppler ultrasonography (TCD) a signiﬁcantly higher
prevalence of PFO in subjects with migraine with aura [28,29]. Fur-
thermore, a study of young cryptogenic stroke patients assessed by
TOE demonstrated an increased prevalence of migraine in patients
with PFO compared to patients without PFO [30]. A retrospective
study showed that patients with migraine who  have PFO assessed
by TCD have higher right-to-left shunting compared to controls
[31]. In a meta-analysis of seven studies [11,28,32–36] it was
demonstrated that the prevalence of PFO in migraineurs ranged
from 40% to 72%, with an odds ratio ranging from 1.87 to 5.88, leav-
ing the authors to conclude that there was  only low-grade evidence
supporting the association between PFO and migraine [37]. In con-
trast, a large cross-sectional multiethnic elderly population-based
study failed to demonstrate an association between PFO, assessed
with transthoracic echocardiography (TTE) and agitated saline, and
self-reported migraine [38]. In addition, a large case–control study
failed to show an association between migraine and PFO assessed
by TTE with second harmonic imaging and TCD [39]. A study using
modern ultrasound technology in combination with a rigorous
saline contrast echocardiogram protocol which allowed more sen-
sitive detection of PFO found no signiﬁcant association between
PFO and migraine, or between small- and moderate-size PFO and
migraine. This study did not have a large enough sample of large-
size PFO to study its association with migraine [40]. The sensitivity
of the echocardiographic PFO detection technique used, which is
known to be different between different imaging modalities [41],
may  be a confounding factor in determining whether a PFO is asso-
ciated with migraine in a particular study.
Evidence from PFO closure trialsIn cases of atrial septal defect, where the predominant shunt-
ing is from left-to-right [42], percutaneous closure of the defect,
which is now a well-established procedure [43], is associated with
a reduction in the occurrence of migraine [44]. With regard to PFO,
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here the shunting is predominantly right-to-left, several studies
ave been carried out to determine whether closure of the defect
ffects migraine frequency.
To date, the Migraine Intervention With STARFlex Technol-
gy (MIST) trial is the only completed randomized double-blind
ham-controlled trial to evaluate the effectiveness of moderate- to
arge-size PFO closure in migraine with aura [45]. The presence of
FO in this study was assessed with contrast TTE because it was a
ow-risk procedure compared to TOE with a high degree of sensi-
ivity and speciﬁcity [46]. Randomizing 147 patients with migraine
nd PFO, the primary end point of headache cessation, and the sec-
ndary endpoints which included a change in the frequency and
everity of headache, and quality of life did not show a statistical
ifference between the PFO closure and sham groups. The authors
hen proceeded to drop two outliers from the PFO closure group
nd claimed that, after recalculation, there was a signiﬁcant reduc-
ion in the median total migraine headache days in the PFO closure
roup compared to the control group [45] – this practice is at best
uestionable and should be frowned upon. Several prospective ran-
omized trials of transcatheter PFO closure in migraine are ongoing
47,48], while others have been terminated because of poor
ecruitment [49,50].
A meta-analysis of 11 studies investigating the role of transcat-
eter closure of PFO on migraine occurrence was reported by Butera
t al. [51]. It included one randomized double-blind, sham con-
rolled trial (the MIST trial) [45], one prospective case–control trial
52], three prospective trials [53–55],  and six retrospective trials
56–61]. Quantitative synthesis of the data demonstrated complete
ure of migraine in 46% (95% conﬁdence interval 25–67%) of cases,
hile resolution or signiﬁcant improvement of migraine occurred
n 83% (95% conﬁdence interval 78–88%) of cases [51].
A more recent small prospective non-randomized study of
igraine patients with PFO assessed with TTE or TOE, and treated
ith transcatheter closure, showed that all 40 patients reported
mproved migraine symptomatology, and all migraine auras were
liminated [62]. Similarly, a prospective non-randomized study of
0 patients with migraine and high risk of paradoxical embolism
ue to PFO assessed by TTE or TOE, demonstrated that transcatheter
losure of the PFO resulted in improvement in symptoms in 87.5%
f patients, and elimination of auras in 97% of those with migraine
ith aura [63]. In a non-randomized, observational prospective
tudy of 305 patients with prior embolic cerebrovascular events
nd with PFO assessed by TTE and conﬁrmed with TCD, who under-
ent percutaneous PFO closure, it was demonstrated that in a
ubset of 77 patients with migraine there was an improvement
n migraine in 86% of cases at 12 months, suggesting sustained
ong-term beneﬁt of PFO closure in migraine [64].
onclusions
Despite the theoretical possibility of PFO causing migraine, the
vailable basic science and clinical evidence supporting such a the-
ry are limited. Results from epidemiological studies examining
he relationship between PFO and migraine are mixed at best.
lthough non-randomized trials have reported improvement of
igraine with PFO closure, the only completed randomized control
rial thus far has failed to support this line of thought. It must also
e emphasized that closure of PFO is not risk-free. Surgical proce-
ures to manage complications of transcatheter interventions may
e needed in up to 8% of cases [65]. Serious complications such
s thrombus formation on the implant device, thromboembolism
elated to the implant device, cardiac perforation, infective endo-
arditis, and cardiac arrhythmias have been reported [13,53,65,66].
Therefore, it can be concluded that currently PFO closure can-
ot be recommended as a routine treatment for migraine for three
[f Cardiology 61 (2013) 256–259
main reasons: (a) the pathophysiological relevance of this proce-
dure in migraine treatment is debatable; (b) the efﬁcacy of this
procedure in migraine treatment is inconclusively proven; and (c)
the complications of this procedure may  be serious and signiﬁcant
in comparison to the non-life threatening nature of migraine. More
research of PFO in migraine is clearly needed before we  can consider
changing our views on the aforementioned conclusions.
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